Although corneal allotransplantation is performed in the immune-privileged cornea, many grafts are still rejected after transplantation. This study examined the role of chemokine receptor D6 expression in a corneal allograft rejection, investigated the modulation of D6 expression in cells, and determined the effect of D6 on graft survival. Interestingly, D6 was highly expressed in CD45 2 cells and the corneal epithelium of accepted corneal allografts. From the mouse corneal allograft model, TGF-b was found to play a key role in D6 up-regulation, leading to reduced CCL2, CCL5, and CCL3. To modulate D6 chemokine binding, a D6MT was developed and showed effective chemokine trapping through SPR and FACS assays. By treating corneal allografts with D6MT, the allograft survival rate was improved, and (lymph) angiogenesis was reduced. Direct allosensitization and DC LN homing was drastically reduced in the mouse corneal allograft model. These findings suggest that TGF-b is a positive regulator of D6 expression, and it is a potential therapeutic target to enhance the survival of corneal allografts.
Introduction
Allograft rejection is an active immune process that includes allosensitization, chemoattraction, migration, and activation of cells. This complex process is mediated by many types of different cells, chemokines, and cytokines [1] [2] [3] [4] [5] . DCs are known to have important roles as initiators and regulators in a wide range of immune-mediated diseases, including corneal allograft rejection [6, 7] . Whereas the suppression of endogenous DC function has been shown to contribute to cancer progression [8, 9] , therapeutic targeting of DCs to suppress their function has been shown to be beneficial in mouse models of autoimmunity [10, 11] and transplantation [6, 12, 13] .
Chemokines and their receptors are essential to initiate the activation and migration of DCs to an insulted area [8, 14] . Chemokines are low molecular weight proteins (8-13 kDa) that play critical roles in the immune and inflammatory responses, with nearly 50 chemokine species and over 15 receptors identified to date [15, 16] . The chemokine receptor D6 is an atypical receptor that acts as a "scavenging receptor" for inflammatory CC chemokines, especially most of the ligands for CCR1-CCR5 [17] . This receptor exhibits a seven-transmembrane domain, similar to that of conventional chemokine receptors, yet lacks the ability to transduce an intracellular signal [18, 19] . The tissue expression of the D6 receptor has been investigated in lymphatic and blood cells but is still poorly understood. Recently, we found that D6 + CD11c + DCs stimulate alloreactive T cell responses that are responsible for corneal allograft rejection [20] . However, the recruitment of D6 + cells in the allotransplanted model, the possibility of resident cell expression of D6, and the mechanisms of D6 enhancement were still unclear.
As the previous work was focused on T cell allosensitization by D6-expressed CD11c + DCs, the objective of this study was to determine the expression pattern in allotransplanted corneal tissue, the role of D6 expression in corneal allograft rejection, and whether the modulation of D6 expression could improve graft survival. Additionally, we generated trap proteins that mimic the D6 receptor by changing the D6 amino-terminal chemokine-binding site. We then used these trap proteins to investigate chemokine-binding efficacy, immune cell activation, LN homing, and corneal allograft rejection. 
MATERIALS AND METHODS

Mice
Corneal allograft surgery
Standard protocols for murine orthotopic corneal transplantation were used, as described previously [3, 21] . In brief, donor center corneas (2 mm diameter) were excised from C57BL/6 mice. Then, the donor cornea was sutured with 11-0 nylon onto the recipient graft beds, prepared by excising a 2.0 mm site in the central cornea of BALB/c mice for allogeneic and C57BL/6 mice for syngenic graft. A topical antibiotic (0.3% ofloxacin ointment) was applied immediately after surgery, as well as immediately after suture removal on Postoperative Day 7. After corneal transplantation, some of the mice were divided into two treatment groups, control (GST) or D6MT. Each substance was administered topically (50 nM/8 ml, once/day) until scheduled death. The detailed methods for eyeball and LN collection are described in our previous publications [22, 23] .
Graft survival was evaluated twice/week over the course of 8 weeks by use of slit lamp biomicroscopy. We used a standardized opacity-grading system that has been used before [20] . In brief, the following standardized opacity grading (ranges 0-5) was used: 0 = clear graft; 1+ = minimal superficial (nonstromal) opacity; 2+ = minimal deep stromal opacity; 3+ = moderate deep stromal opacity; 4+ = intense deep stromal opacity; and 5+ = maximum stromal opacity. Rejection was defined as a score of 2+ or greater for 2 consecutive examinations.
Flow cytometry
Single-cell suspensions of corneal samples for surface-marker staining were prepared as described previously [3] . In brief, before preparing a single-cell suspension, more than 4 corneas were pooled from each experiment condition to obtain enough cells. Absolute numbers for each sample were determined by use of a hemacytometer. The staining was performed by use of the following antibodies: anti-CD207 FITC, anti-CD11b PE, anti-CD25 PE, antiFoxp3 PE-Cy5, anti-CD11c FITC, anti-D6 FITC, anti-CCR7 Alexa Flour 488, anti-Ia/Ie PE, anti-Gr1 PE, anti-CD4 FITC, and anti-CD8 Alexa Flour 647 (eBioscience, San Diego, CA, USA) and analyzed on a FACSCalibur and FACSAria flow cytometer (BD Biosciences, Franklin Lake, NJ, USA). For intracellular cytokine staining (anti-IFN-g PE and anti-IL-6 FITC; BioLegend, San Diego, CA, USA), cells were stimulated in vitro with 50 ng/ml PMA (Sigma-Aldrich, St Louis, MO, USA), 750 ng/ml ionomycin (Sigma-Aldrich), and 5 ml Golgi plug (BD Biosciences) in a 96-well plate and incubated at 37°C for 4 h before staining. To avoid nonspecific staining, FcR block with the FcR mAb (CD16/32) was performed for 20 min at 4°C. Cells were washed and resuspended in fixation/permeabilization solution (BD Cytofix/Cytoperm Kit; BD PharMingen, San Diego, CA, USA), and cytokine staining was performed per the manufacturer's protocol. Gates were determined by isotype staining, performed on the same organ.
Western immunoblot
Total protein concentrations were determined by use of the bicinchoninic acid protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein were resolved by SDS-PAGE, containing 8% (w/v) or 10% (w/v) polyacrylamide. Proteins were then transferred to polyvinylidene difluoride membranes, which were probed overnight with primary antibodies, followed by HRP-conjugated secondary antibodies. Immunoreactive bands were visualized by use of ECL.
Real-time PCR
RNA was isolated with the RNeasy Micro Kit (Qiagen, Hilden, Germany) and reverse transcribed by use of the Superscript III Kit (Invitrogen, Carlsbad, CA, USA). Real-time PCR was performed by use of TaqMan Universal Master Mix and preformulated primers. The detailed information on the primers is described in Supplemental Fig. 1 . The results were analyzed by the comparative threshold cycle method and normalized by use of GAPDH as an internal control.
IHC and immunofluorescein staining
The IHC and immunofluorescein staining methods for cornea were performed as described previously [24] .
Plasmids cDNAs encoding fragments of D6MT were amplified by PCR from a HeLa cell cDNA library by use of Pfu polymerase (Stratagene, La Jolla, CA, USA). The primers were 59-AAA (GAA TTC) GCC GCC ACT GCC TCT CCG CAG-39 (top strand) and 59-AAA (CTC GAG) TTT GCC AAA GGA CAC CAC TGC-39 (bottom strand). Nucleotides were added to make BamHI and XhoI restriction sites in parenthesis. The synthesized, double-stranded oligonucleotides were annealed and inserted into the BamHI-and XhoI-digested pET-41a vector (Novagen, Johannesburg, South Africa), which has aminoterminal GST and polyhistidine (63 His) tags, as well as a carboxy-terminal polyhistidine tag for purification. The sequence details of D6MT are in Supplemental Fig. 2 .
Purification of proteins
pET-41a vectors encoding D6MTs were transformed into Escherichia coli BL21 (DE3). The selected BL21 colonies were cultured in 3 ml LB medium overnight. The next day, cultures of BL21 were used to inoculate 250 ml LB medium. At OD 600 = 0.5, 0.1 mM isopropyl b-D-1-thiogalactopyranoside was added to induce fusion protein expression for 7 h at 37°C. After centrifuging the culture at 10,000 g for 10 min, the bacterial pellets containing D6MT were resuspended in 10 ml binding buffer without urea and sonicated. Again, the disrupted cells were centrifuged at 14,000 g for 20 min, and then the supernatant fraction was used for further purification. The supernatant fraction was applied to a histidine-binding resin (Novagen) that was preequilibrated with distilled water, charge buffer (50 mM NiSO 4 ), and binding buffer and allowed to flow by gravity. The column was washed with 10 vol binding buffer, 6 vol wash buffer, and then elution buffer. To eliminate imidazole, eluted fraction were dialyzed to a buffer containing 50 mM TrisHCl, 5 mM CaCl 2 , 150 mM NaCl, and 0.5 mM 2-ME with a pH of 7.5. Dialyzed GST-His D6MT proteins were resolved by 10% (w/v) SDS-PAGE. After electrophoresis, the gels were stained with Coomassie blue R-250 and then destained by standard methods.
SPR (Biacore) analysis
The detailed protocols for the SPR assay have been described previously [24] . In brief, D6MT was immobilized onto CM5 sensor chip (GE Healthcare, Little Chalfont, UK) surfaces by use of an amine-coupling kit (GE Healthcare), according to the manufacturer's instructions. Protein binding was measured at a flow rate of 10 ml/min in buffer containing 145 mmol/L NaCl and 10 mmol/L HEPES (pH 7.4) containing various concentrations of analyte chemokine proteins, unless indicated otherwise. Analyses were performed by use of a Biacore 3000 instrument (GE Healthcare).
Collection of chemokine-enriched supernatants from mouse peritoneal macrophages counted by use of a "Countess" automated cell counter (Invitrogen). To prepare splenic lymphocytes, the spleen was weighed, placed on steel mesh in a Petri dish, and by massaging the spleen capsule with a glass rod, the cells were released into the buffer. The cells were then washed three times in HBSS before proceeding.
Splenic lymphocytes or peritoneal macrophages were resuspended to 7 3 10 6 cells/ml in RPMI. The cells were stimulated by culturing in FBS-free RPMI for 24 h with LPS (10 ng/ml; Sigma-Aldrich), PMA (50 mg/ml; SigmaAldrich), and ionomycin (1 mg/ml). Then, 1 ml of the supernatant fraction from each cell condition was mixed with 1.0 mg/ml D6MT and the same molar mock (GST) for 3 h by an agitator in 4°C. To collect D6MT and/or the GSTbinding peptide, a GST pull-down assay was performed. The detailed collection methods were published previously [21] .
LC-MS/MS assay
A peptide mixture dissolved in 10 ml 0.2% formic acid was centrifuged at 13,000 g for 10 min before analysis with LC-MS/MS by use of a LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Peptide separation was conducted by use of a nanoflow LC system (Micro-Tech Scientific, Vista, CA, USA) with a C18 reverse-phase column at a flow rate of 500 nl/min. A gradient of 5-32% acetonitrile in 0.1% formic acid was applied .240 min. The instrument was operated in positive ion mode, with the electrospray ionization voltage set at 2.4 kV and the collision energy set at 35%. Raw data were acquired in profile mode by use of Xcalibur software 2.2 (Thermo Fisher Scientific). Each full scan MS spectrum (m/z, 300-1600) was followed by MS/MS acquisition. Survey spectra with a resolution of 60,000 at 400 m/z after accumulation to a target value of 1,000,000 were acquired for collision-induced dissociation fragmentation on the 5 most intense ions from the MS spectrum. The MS raw data analysis was described in Supplemental Fig. 3 .
ELISA
After the corneas were prepared, as described above, the concentration of each cytokine was measured by ELISA. The murine ELISA kits for IFN-g, IL-1b, and IL-6 were purchased from (R&D Systems, Minneapolis, MN, USA). IL-10, IL-23, and IL-12p40 antibodies for ELISA were from eBioscience. CXCL-10, CXCL-1, CCL5, and CCL4 antibodies were from Invitrogen. The detailed methods were described previously [24] .
Flow cytometry for competitive chemokine-binding inhibition assay 
Boyden chamber assay
Inhibition of CCL2-and CCL5-induced RAW264.7 cell chemotaxis was evaluated in Boyden chambers (5 mm pore sized; Millipore, Danvers, MA, USA). In brief, RAW264.7 cells were isolated by EDTA treatment and suspended at a final concentration of 1 3 10 6 cells/ml in RPMI containing 5%
FBS. The cell suspension (100 ml) was loaded into each of the upper wells.
With the presence of CCL2 or CCL5 (100 ng/ml) in the lower chamber, D6MT (50 nM;5 mM) or the same molar GST was added to the lower chamber medium for use as a chemoattraction inhibitor. Cells were incubated for 9 h at 37°C in 5% carbon dioxide. Then, the migrating cells adhering to the undersurface of the filters were fixed and stained with crystal violet and counted. CCL2 or CCL5 (100 ng/ml) was used as a positive control. Data were given as the mean of 4 experiments (*P , 0.05 **P , 0.01 † P , 0.05).
Statistics
All data are expressed as mean 6 SD. Differences between groups were examined by Student's t-test or multivariate analyses by use of Newman-Keuls test or ANOVA, followed by the Bonferroni procedure for comparison of means by use of SPSS 21.0 software (SPSS, Chicago, IL, USA). P , 0.05 was considered statistically significant.
RESULTS
Expression of D6 decoy receptor in corneal allografts
As D6 expression on the ocular surface is unknown, D6 mRNA expression in mouse organs and tissues was determined and compared by use of RT-PCR. Interestingly, D6 mRNA was found to be highly expressed under normal conditions ( Fig. 1A and Supplemental Fig. 4 ). D6 mRNA expression in ocular tissue was relatively high compared with other tissues and was comparable with that of testis. Next, D6 expression was determined in corneal allografts by flow cytometry and IHC staining. Interestingly, although the D6 + CD45 + cells were recruited into the corneal allograft (0.01% in nonoperated cornea; ,1.1% in corneal allografts), the largest difference was found in D6 + CD45 2 cells (Fig. 1B) . At 3 weeks after the allograft procedure, the D6 + CD45 2 cell frequency in the accepted grafts was increased to 3.5%, which was elevated significantly compared with that of rejected grafts (,0.1% through 35 days after surgery). Moreover, in cases of rejected graft, the frequency of the D6 + CD45 2 cell was reduced significantly compared with that of the nonoperated cornea. Although we used a CD45 marker to differentiate corneal residence cells from infiltrated leukocytes, some leukocytes might be CD45 2 , especially if they were from a stem-cell lineage.
Therefore, IHC staining was performed to localize D6-expressing cells topographically in the corneal allografts. In IHC staining, most D6-expressing cells were found in the corneal epithelium with some stromal cells (Fig. 1C) . Strikingly, D6 expression was clearly detected in the entire corneal epithelium of accepted allografts. There were some infiltrated D6 + leukocytes found in the stromal layer underneath the high D6-expressing epithelium. However, in the corneal beds of rejected allografts, D6-expressing cells in the epithelium and stromal infiltrated D6 + cells were hardly found. To clarify D6 expression patterns further in the grafted corneas, cells in the allograft were sorted with the CD45 marker, and then, D6 mRNA levels were measured. The D6 expression was increased significantly in CD45 2 cells (Fig. 1D ).
Chemokine and cytokine expression between accepted and rejected corneal allografts
As D6 expression was elevated in the corneal epithelium of accepted allografts, the level of chemokine expression was determined by ELISA in accepted and rejected allografts. Interestingly, CCL2, CCL5, CCL11, and CCL24 were decreased significantly in expression in accepted allografts compared with rejected allografts (Fig. 2A) . However, CCL3 and CCL8 expression was not different between the 2 groups. As IFN-b, IFN-g, TGF-b, and IL-1a have been shown to induce D6 [19, 25] , expression of these cytokines was compared between accepted and rejected allografts. At 2 weeks after surgery, IFN-g and TGF-b expression was increased significantly in accepted allografts compared with rejected allografts (Fig. 2B) . To determine the IFN-g and TGF-b effect on the D6 expression, D6 expression was measured in cultured corneal epithelial cells treated with these cytokines. When treated with TGF-b, D6 expression was increased, as shown by the immunoblot (Fig. 2C  and D) . TGF-b-induced D6 expression was down-regulated by treatment with M6P (Fig. 2D) . However, IFN-g and its receptors were not detected in mouse corneal epithelium in vivo (data not shown). Then, the expression of both TGF-bRs was found in normal corneal epithelium and some stromal keratocytes ( Fig. 2E) . Interestingly, TGF-bR1 and -R2 expressions were only up-regulated in corneal epithelium of accepted allografts.
Generation of D6MT and determination of chemokine-binding affinity
To enhance the chemokine decoy activity in corneal allograft and regulate the chemokine expression, D6MTs were designed by modifying the amino-terminal region of D6. By Coomassie blue staining and immunoblot, a single band of D6MT was confirmed ( Supplemental Fig. 2) . To determine the chemokinebinding affinity of D6MT, LPS-activated mouse splenocytes were lysed and incubated with D6MT or control GST. The samples were resolved on an SDS-PAGE gel. The silver stain of the gel showed multiple bands within the region of typical molecular weight for chemokines in cell lysates treated with D6MT (Fig. 3A,  lane 13) but not with GST (Fig. 3A, lane 12) . Then, the resolved bands under the 18 kDa area were cut and analyzed with LC-MS/ MS. From the LC-MS/MS analysis, a total of 5 chemokines was confirmed ( Fig. 3B and Supplemental Fig. 5 ). Furthermore, known D6-binding chemokines, including CCL8, CCL11, CCL22, and CCL23, did not bind to D6MT. The further information from the Mascot search results are in Supplemental Fig. 5 .
To address whether D6-binding chemokines interact directly with D6MT, an SPR assay was performed. Initially, chemokinebinding affinity for immobilized D6MT was measured for several concentrations of chemokines (Fig. 3C) . From the SPR assay, chemokines CXCL1 and TGF-b did not bind with D6MT with micromolar affinity (data not shown). However, CCL2, CCL4, and CCL5, which were found to bind D6MT in the LC-MS/MS assay, interacted with D6MT with nanomolar affinity.
A cellular chemokine-binding competition assay was also conducted to assess the ability of D6MT to inhibit D6 binding under conditions that more closely reflect the in vivo environment. RAW264.7 cell surfaces were immunostained for CCL2, CCL4, CCL5, TGF-b, and IL-6 in the absence and presence of equal molar amounts of D6MT. The results clearly showed that all chemokines and control cytokines (TGF-b and IL-6) bind with RAW cells (Fig. 3D, red line) . In the presence of D6MT, however, immunostaining is reduced for all 3 chemokines (Fig. 3D, green line) ; CCL4 was reduced almost to the level of unstained RAW cells. Incomplete inhibition was observed for CCL2 and CCL5. As expected, the binding-control cytokines TGF-b and IL-6 were completely unaffected by incubation with D6MT, confirming that inhibition by D6MT was chemokine specific. Additionally, we confirmed the migration-inhibitory effect of D6MT with the Boyden chamber assay. The facilitated RAW cell migration by CCL2 and CCL5 was inhibited significantly by D6MT in a dose-dependent manner (Fig. 3E) .
Corneal allograft survival through treatment with D6MT
Then, D6MT was tested in an in vivo model for an effect on corneal graft survival and chemokine inhibition. For 8 weeks after corneal allograft surgery, the rejection rate was reduced significantly by treatment with D6MT, 50 nM/day compared with same molar treatment of the GST protein (Fig. 4A) . The opacity and neovascularization in the graft were reduced significantly, as shown by serial observation (Fig. 4B and C (Fig. 4D) .
In draining LNs, CD11c + and CD11b + cell frequencies were decreased slightly after treatment of D6MT (Fig. 4E) . Surprisingly, CD207 + cells were reduced significantly in draining LNs, as well as the ocular surface (Fig. 4E) . The CD25 + Foxp3 + regulatory T cell population was increased from 4.6 to 9.3 at 2 weeks after D6MT treatment (Fig. 4F) . Next, inflammatory cytokines and chemokines were measured in the transplanted corneas and were found to be decreased significantly in the D6MT-treated group. IFN-g and IL-1b expression was reduced by 33% and 47%, respectively, relative to the mock-treated group (Fig. 4G) . Interestingly, IL-1b, CXCL-10, and CXCL1 expression was nearly identical to wild-type levels in the D6MT group. IL-12 and RANTES also decreased significantly. However, IL-23 was not reduced by D6MT.
Inhibition of angiogenesis and lymphangiogenesis by treatment with D6MT
Within days following corneal transplantation, both lymphatic and blood vessels grew toward the donor tissue (data not shown). At 3 weeks after the graft procedure, the D6MT treatment group showed significantly less lymphatic (LYVE-1) and blood (PECAM) vessels than the mock-treated group (Fig. 5A-C) . In the mock-treated condition, well-developed lymphatics were found in the donor graft and the recipient. The mRNA expression of VEGFs, their receptors (VEGFRs), and dll4 were measured at 2 weeks after the graft procedure (Fig. 5D) . VEGF-A, dll4, and VEGFR2 expression was enhanced in CD11b + and CD11b 2 cells in the allograft. VEGF-C and VEGFR3 mRNA was increased in CD11b 2 cells but not in CD11b + cells. Interestingly, VEGF-A, VEGF-C, and VEGFR2 and 3 expressions decreased significantly with D6MT treatment, but VEGFR1 expression was decreased in CD11b + and CD11b 2 cells of the D6MT-treated group compared with the mock-treated control (P , 0.01). MHC class II (I a /I e ) expression and CCR7-expressing cells were also measured (Fig. 5E) . MHC class II expressed in the CD11c population was decreased with D6MT treatment. CCR7 + is an essential homing molecule that controls APC and T cell migration to secondary lymphoid organs [26] . CCR7 + cells were also reduced significantly in the cornea bed with D6MT treatment (Fig. 5E ).
DISCUSSION
Although D6 expression and function have been investigated extensively for more than 1 decade, the mechanism by which D6 expression is up-regulated remains poorly understood. Furthermore, clinical applications by use of D6 to reduce the inflammatory response have not been investigated. Here, we show that D6 can be up-regulated by TGF-b, and a mimicking trap can be used to prevent allograft rejection by inhibiting angio-and lymphangiogenesis, as well as inflammatory cell infiltration. Previously, we demonstrated that D6 expression by DCs also has a proinflammatory effect by supporting T cellmediated alloimmunity [20] . However, the study only focused on CD11c cells and did not investigate the whole mechanism of D6 expression in allograft-related immune activation. In this study, we set out to investigate D6 expression patterns and specific expressing cells in real corneal allografts (not specific cells) by use of IHC and FACS assay. The most remarkable change in D6 expression was found in the donor corneal epithelium of allograft acceptors. Therefore, we designed this study to determine the role of D6 in corneal epithelium, as well as infiltrating cells, in corneal allografts. Interestingly, D6 + leukocytic infiltration was found to have little impact on high-risk corneal allograft survival. Instead, D6 expression of donor tissue resident cells (corneal epithelium) was more important than the D6 expressed infiltrated host cells. These findings led us to delineate the cytokine that up-regulates local D6 expression and develop D6MT for trapping chemokines. Up-regulation of proinflammatory chemokines and the inability to resolve prolonged inflammation are major contributors to transplant pathology. A few minutes after organ transplantation, chemokines are released by the graft and the recipient, which trigger the recruitment of inflammatory cells [27, 28] . One potential target for blocking allograft rejection is downregulation of this inflammatory cell recruitment. This recruitment process is complex and involves the interaction of leukocytes with soluble mediators, such as chemokines [16, 29] . Although chemokines are important targets for development of anti-inflammatory drugs, there is extreme pleiotropy and redundancy in the chemokine system, making it difficult to target individual molecules [30, 31] . We have found elevation of chemokines in rejected corneal allografts compared with accepted grafts. Although the non-D6 decoy chemokines, CXCL1 and CXCL10, were elevated in rejected corneal beds, many of other D6-associated chemokines, such as, CCL2, CCL4, CCL5, CCL13, and CCL18, were up-regulated. Thus, we have selected D6 as a potential therapeutic target and have developed D6MT.
The role of the D6 decoy chemokine receptor in corneal allograft rejection Previously, D6 expression has been studied extensively in lymphatic endothelial cells, blood cells, alveolar macrophage, and trophoblasts in the placenta [32] [33] [34] [35] . However, there are few studies on D6 expression in nonimmune cells, such as the surface epithelium. Singh et al. [36] recently reported elevated D6 in uninvolved keratinocytes of psoriasis patients. From this study, the elevated D6 expression in uninvolved psoriatic skin lesions is compatible with a role in the local suppression of inflammatory chemokine activity, thereby blocking psoriatic lesion development. Additionally, mucosal stromal cells were found to express D6 in an experimental colitis model [37] .
Here, we report that D6 is highly expressed only in accepted allografts of corneal epithelium compared with rejected allografts and normal cornea tissue. Moreover, the stromal infiltration of inflammatory cells and expression of chemokine levels were reduced significantly when D6 is highly expressed. Interestingly, D6 was also found in high levels in other immuneprivileged sites, including the testes and the placenta in this and other studies [34, 38] . Moreover, D6 expression was localized to the limbus and the peripheral cornea, sites that serve as gatekeepers for immune cell trafficking (data not shown). D6 was also highly expressed in retinal pigment epithelium and retinal tissue, the immunologically active areas of the eye. Taken together, it is possible that D6 may play an important role in preventing immune cell invasion to the cornea.
Besides the high expression of D6 in corneal epithelium, D6 + CD45 + mononuclear cells were recruited to the stromal area during the early inflammatory period (Fig. 1C) . We found that D6 + CD45 + mononuclear cells may express CD11b or CD14 (data not shown). These cells are located in the recipient cornea stroma. Interestingly, the accepted allografts had .10-fold higher frequencies of these cells at each tested time-point after the procedure. Initially, we were interested in the D6 + CD45 + cell population. However, the abundance of these cells was very low (,2% in all time-points tested), so it was difficult to investigate the phenotypical and functional characteristics of these cells. Moreover, by detail flow analysis, we did not find any difference in CD11b
+ and CD11c + cell infiltration in donor cornea when D6 + CD45 + cells were present. However, up-regulation of D6 in corneal epithelial cells correlated with reduced inflammatory cell infiltration. Lastly, we did not find any difference between accepted and rejected allografts in D6 + CD45 + mononuclear cells in the peripheral blood, bone marrow, or draining LNs until 8 weeks after grafting (data not shown). Thus, D6 expression in allograft epithelium may play a central role in the immune tolerance of corneal allografts by reducing inflammatory cell infiltration through a chemokine decoy mechanism and reduced angio-and lymphangiogenesis. We found elevated expression of proinflammatory chemokines (e.g., CCL2, CCL3, CCL5) in rejected allografts. Interestingly, the chemokine expression profile in rejected allografts was quite similar to other highly vascularized organ transplantation rejections, such as heart or liver [27, 39, 40] . Bradford et al. [27] reported that CCL2 and CCL5 expression positively correlated with cardiac allograft rejection, which is in accordance with our study. Additionally, our result and other analyses showed significant IFN-g and IL-2 elevation [2, 41] . These data may imply that the process of . RAW264.7 were isolated and loaded into each of the upper wells, and with the presence of CCL2 or CCL5 (100 ng/ml) in the lower chamber, D6MT (50 nM;5 mM) or the same molar GST was added into the lower-chamber medium. Cells were incubated for 9 h. Then, the migrating cells adhering to the undersurface of the filters were fixed and stained with crystal violet and counted. Data were given as the mean of 4 experiments (**P , 0.01).
corneal allograft rejection is quite similar to that of other solid organ transplantation rejections, at least at the initial stages of allograft rejection through chemokine expression. Another interesting finding by D6MT treatment was reduced IL-12 and CCR7 expression in the allografted corneas. After 2 weeks of D6MT treatment, CCR7 + CD11b + cells and IL-12 concentrations in the allograft were decreased significantly compared with the mock-treated control. IL-12 and CCR7 are well-known markers for mature APCs, which are able to simulate naïve and memory T cells [42] [43] [44] [45] . Therefore, these data may suggest that the APC activation process can be suppressed, at least in part, by reducing proinflammatory chemokines through D6MT treatment.
The development of D6MT for decoying specific chemokines in corneal allograft rejection
Chemokine receptor antagonists, with the exception of the CCR5 antagonist (which is a registered antiretroviral agent), have not lived up to their therapeutic promise [30, 31] . There are several possible reasons for these failures. Chemokine receptor redundancy has been proposed as 1 explanation to account for these failures. Simply targeting one chemokine or chemokine receptor might not provide a therapeutic effect [31] . Therefore, it has been suggested that promiscuous chemokine blockers may be the more appropriate way to treat diseases and conditions that originate from complex chemokine activation, such as allograft rejection.
We targeted CC chemokines themselves by creating a mimicking decoy receptor. Interestingly, the results were quite successful; the IC 50 value for CCL2, CCL3, CCL5, and CCL13 was found to be effective in nanomolar concentrations. Previously, promiscuous chemical chemokine receptor antagonists, such as A2-acetamide (Takeda, Tokyo, Japan), showed an IC 50 of 450 nM for CCR1 and 32 nM for CCR3. The compound UCB35625 was found to have an IC 50 of 9.6 nM for CCR1 and 93.7 nM for CCR3 [30, 46, 47] . Compared with these reports, the results from D6MT are comparable in chemokine-binding affinity with other successful chemokine inhibitors. Therefore, D6MT could be tested to treat inflammatory or autoimmune diseases that have been shown to have heterogeneous biologic targets (e.g., rheumatoid arthritis or multiple sclerosis).
Lymphangiogenesis and chemokine expressions by D6MT
Neither lymphatic vessels nor blood vessels are present in the cornea; afferent lymphatic vessels (from the afferent arm of the immune reflex arc) and efferent blood vessels (from the efferent arm of the immune reflex arc) are responsible for the trafficking of immune cells related to allograft tolerance or rejection after corneal transplantation. We showed that angiogenesis is decreased significantly in accepted corneal allografts. As blood vessels originate from the efferent arc, a nonvascularized graft is more likely to be accepted. In our study, we found very few lymphatic vessels in the donor graft area after treating with D6MT. In addition, the maturity of lymphatics, which were determined by their continuity and branching, was reduced significantly after D6MT treatment. We could not determine which specific chemokine was decoyed by D6MT to abrogate lymphangiogenesis in this study. However, a complex signaling pattern of chemokines and cytokines is believed to coordinate lymphangiogenesis and angiogenesis. Therefore, to block more effectively angiogenesis and lymphangiogenesis simultaneously, a multichemokine trapping method is likely to be superior to targeting a single, specific chemokine.
Interestingly, the expression of CXCL1, CXCL10, and VEGF-C, which account for lymphangiogenesis [48] [49] [50] , was decreased in accepted allografts and after D6MT treatment. However, in our D6MT SPR assays, we failed to find the direct physical affinity between D6MT and C-X-C chemokines or VEGF-C (data not shown). It is possible that these cytokines/chemokines may be down-regulated indirectly by the inhibition of the proinflammatory chemokines trapped by D6MT. In addition, we found the many lymphatic vessels were growing in rejected donor grafts without blood vessels. In most inflammatory conditions, including corneal suture, angiogenesis occurs more readily than lymphangiogenesis. Interestingly, the observation of welldeveloped lymphatics and less-developed blood vessels was found frequently in the rejected corneal allografts. Therefore, some cytokine(s) and/or chemokine(s) may play important roles in the development of lymphatic vessels in the absence of blood vessels in the rejected allograft bed, and this pathway may be a selective target for antilymphangiogenic therapy. In addition, it may imply that direct sensitization by donor cells through welldeveloped lymphatics is also important for allograft rejection, as well as indirect sensitization.
There are several limitations in the present study. The D6MT efficacy was shown only in an in vivo mouse model. However, in many cases, the structural homology of chemokines and their receptors between mice and humans are significantly different [51] . For example, IL-8, MCP-4, and eotaxin-2/3 chemokines, which are present in humans, have not been found in mice. Thus, the ability of D6MT in human diseases might be different from that shown here and should be investigated in the future. Second, the pharmacodynamics and pharmacokinetics for D6MT are not well documented. The degradation mechanism after D6MT-treated conditions. Four independent experiments were performed, and median values are shown. (B and C) Length of blood vessels (B) and lymphatic vessels (C) were measured at 2 weeks after keratoplasty with D6MT-or mock (GST)-treated (50 nM/day) conditions. Photos were taken from a whole-mount corneal sample by use of epifluorescein microscopy. The length and branching were quantified in each quadrant of the whole corneal flap (Image Grabber version 1.4; Scion, Torrance, CA, USA) compared with the mock-treated control. All of the experiments were performed and analyzed in triplicate for 3 separate experiments. (D) mRNA expression of angiogenic and lymphangiogenic markers in D6MT-or mock-treated corneal allografts was determined by qPCR. At 2 weeks after transplantation, corneal allografts were harvested, minced, and prepared for cell sorting by use of anti-CD45 antibodies. After cells in the graft were separated as CD45 + or CD45 D6MT binds with chemokines has not been studied. These studies will be critical for clinical application of D6MT. Lastly, although we proved the direct protein-protein interaction between D6MT and chemokine, it is still possible that D6MT may also act as an immunosuppressive agent through nonspecific binding. Therefore, the possibility of nonspecific binding of D6MT with other immune-related receptors should be investigated.
In conclusion, the present study describes the upregulation of D6 expression in the corneal epithelium of successfully allografted corneas, which reduced the recruitment of inflammatory cells. We also revealed an important role of D6 in the establishment of anti-inflammatory activity by decoying D6-binding chemokines. Antagonists of the chemokine system represent a promising anti-inflammatory strategy, relevant not only to graft rejections but also to other medical therapeutics, including other organ transplantation, autoimmune disease, and blood cell malignancy. Therefore, D6MT should be investigated further as a strategy to treat these diseases and modified to target other proinflammatory chemokines.
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